Hold the meeting
Approved by the Chinese Society of Health Information and Health Medical Big Data, on June 2, 2023, the sixth meeting of the Ophthalmology Professional Committee of the Chinese Society of Health Information and Health Medical Big Data was successfully held in Beijing. The purpose of this conference is to elect a new sub-committee to promote the development of ophthalmic information construction. Secretary-general Yu Xiaobing presided over the conference.
Background of the meeting
Health care is related to the well-being of every citizen, and in 2017, the ophthalmology Special Committee led by Professor Dai Hong of Beijing Hospital was formally established. The establishment of the ophthalmology Professional Committee will further promote ophthalmology services, clinical, scientific research and other work, promote ophthalmology information to reach a new level, drive grassroots medical institutions, and provide better medical services for the majority of people.
The purpose of Chinese Health Information and Big Data Association (CHIBDA) is: Unite the majority of health and family planning statistics and information construction workers in the country, implement the national health and family planning guidelines and policies, focus on the development requirements of health and family planning, focus on the research and practice of health and family planning statistics and information construction, promote the improvement of the level of health and family planning statistics and information construction, and promote the improvement of the professional level of health statistics and information personnel. Promote the popularization and promotion of knowledge related to health statistics and information construction, promote the improvement of national health level and the modernization management level of national health and family planning undertakings, serve the overall situation of health and family planning reform and development, and serve the promotion of the construction of healthy China.
Conference site
On June 2, 2023, Secretary-General Yu Xiaobing, the moderator of the General assembly, read out the resolution of the second session of the Ophthalmology Committee members, members of the Standing Committee, deputy chairman, chairman, Secretary-General and deputy Secretary-General. Secretary-general Yu Xiaobing said that their participation better promoted the information construction of ophthalmology.
At the meeting, Director Dai Hong of Beijing Hospital continued to serve as the chairman. Xu Xun, Director of Shanghai First People’s Hospital, Tang Shibo, President of Aier Eye Hospital, Wei Wenbin, Vice president of Beijing Tongren Eye Center Affiliated to Capital Medical University, Qu Jia, President of School of Optometry of Wenzhou Medical University, Bi Hongsheng, president of Shandong University of Traditional Chinese Medicine Eye Hospital, and many other major ophthalmology leaders were elected as vice chairman of the committee, and Chen Xinjian, chairman of Big Vision was also elected as Vice chairman.
Chen Xinjian and his team are committed to the technological innovation of ophthalmic image artificial intelligence, and have made fruitful achievements in the field of ophthalmic image analysis and auxiliary diagnosis research. After serving as the deputy chairman, he will give full play to the advantages of the professional team in the field of ophthalmic AI, use emerging technologies such as AI large-scale data models, tap the great value of ophthalmic medical big data, realize the corporate mission of “early detection of every pair of problematic eyes, and give the best treatment plan”, and make positive contributions to improving the national eye health level.
Big Vision
Big Vision is a high-tech enterprise founded by national talents. The company focuses on the research and development, production and sales of ophthalmology image artificial intelligence analysis and diagnosis software and hardware systems. Its technology research and development capability ranks among the top in the world, and it is committed to becoming a global ophthalmology artificial intelligence leading brand. At present, it has won more than 80 innovative achievements and patents, and won the highest award in the field of artificial intelligence “Wu Wenjun Artificial Intelligence Technology Invention Award” first prize, “Jiangsu Province Science and Technology Award” second prize and other honorary awards.
Big Vision automatic artificial intelligence OCT landing continues to accelerate, advanced eye AI can serve more people; MIAS-3000 is undergoing multi-center clinical trials and is expected to become the world’s first ophthalmic OCT image AI-assisted diagnostic system approved for Class III medical device registration; Vision screening instrument has been successfully applied in the school children and adolescents myopia screening project, dry eye detector will be approved in the near future medical device registration certificate, the company’s product line continues to enrich. As the pioneer of ophthalmic AI, Big Vision has been adhering to the original intention of enabling eye diagnosis and treatment with advanced AI, facing difficulties, pushing forward, and contributing scientific and technological strength to the cause of national eye health.
Ophthalmic artificial intelligence series products
(Myopia Prevention and early Warning System for children and Adolescents)
In the future, Big Vision will continue to use advanced ophthalmic AI technology to empower ophthalmic diagnosis and treatment, and move forward on the road of universal eye health.
No comments yet.